BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Helen Ogorman ,Brennan Doyle ,Frank Yocca ,Erik Kopp ,Frances Levin ,Centers For Disease ,White House Council Of Economic Advisers ,National Institute On Drug Abuse ,Department Of Psychiatry At Columbia University ,National Institutes Of Health ,Bioxcel Therapeutics Inc ,Nasdaq ,Columbia University ,While The Company ,Professor Of Psychiatry At Columbia University ,Bioxcel Therapeutics ,National Institute ,Drug Abuse ,National Institutes ,Disease Control ,White House Council ,Economic Advisers ,Substance Use Disorders ,New York State Psychiatric ,Multiple Principal Investigator ,Project Director ,Sandra Comer ,Chief Scientific Officer ,Xcel Therapeutics ,Onkosxcel Therapeutics ,Private Securities Litigation Reform Act ,Quarterly Report ,House Release March ,Resume ,Careers ,Ioxcel Therapeutics Announces Nih Nida Grant To Columbia University Support Further Studies Of Bxcl501 Sublingual Dexmedetomidine For Treating Opioid Withdrawal ,Iospace ,Advice ,